Auto Fetch Location
Auto Fetch Location
We never post without your permission
Facebook
Twitter
Copy Link
Whatsapp
After Covishield and Covaxin, Corbevax is approved as a booster
Total Views:
20
Total Likes:
0
Published By:
Peeyush Ghalot
Published On:
07-06-2022
The Drug Controller General of India (DCGI) has authorised CORBEVAX® COVID-19 vaccine as a heterologous COVID-19 booster dosage for people aged 18 and above after 6 months of primary immunisation (two doses) with COVAXIN or COVISHIELD vaccines for limited use in emergency situations. BE's CORBEVAX® is the first heterologous COVID-19 booster vaccine to be authorised in India. BE recently submitted its clinical study results to the national pharmaceuticals regulator, VG Somani, who gave permission following a thorough review and consultation with the central drugs standard control organization's Subject Experts Committee. Clinical study data demonstrated that Corbevax booster dosage offered considerable augmentation in immune response and outstanding safety profile necessary for a successful booster. The company completed a multicentre Phase 3 placebo-controlled heterologous booster clinical study in 416 participants ranging in age from 18 to 80 years old who had received two doses of either Covishield or Covaxin at least 6 months prior to receiving Corbevax as a booster dose. To arrange a Corbevax vaccination appointment, utilise the Co-WIN app or the Co-WIN website. 51.7 million doses of Corbevax have been given to children in the United States thus far, with 17.4 million completing the two-dose schedule. BE has so far provided the Indian government with 100 million doses of the vaccine.
